# BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

> **NCT07328581** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **iCell Gene Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)

## Interventions

- **BIOLOGICAL:** ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following cyclophosphamide-only lymphodepletion

## Key facts

- **NCT ID:** NCT07328581
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328581, "BCMA-CD19 cCAR T for the Treatment of Refractory Lupus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07328581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*